Drug intelligence / Profile preview

LB-DTK-COV19

Development stage: Phase 1
Lead developer: LucasBio
Modality: Cell Therapies
Administration: Intravenous

Overview

LB-DTK-COV19 is an autologous T-cell therapy developed by LucasBio for the treatment of prolonged SARS-CoV-2 infection, particularly in moderately immunocompromised patients who are refractory to standard care. The product consists of T cells harvested from the patient, expanded ex vivo, and sensitized to SARS-CoV-2 antigens. Upon re-infusion, these antigen-specific T cells are intended to recognize and eliminate virus-infected cells, thereby reducing viral load and alleviating clinical symptoms. It is currently being evaluated in clinical trials for its safety and efficacy in clearing persistent viral infections.

Other names: autologous SARS-CoV-2-specific T cell therapy

Targets

pMHC (Peptide-MHC complex family)SARS-CoV-2 nucleocapsid protein–derived peptides presented by HLASARS-CoV-2 spike protein-derived peptide-HLA complex

Beyond the preview

Go deeper on LB-DTK-COV19.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on LB-DTK-COV19.